This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Medco To Present Results Of National Study On Effect Of Genetic Testing On Patient Medication Adherence At The American College Of Cardiology 61st Annual Scientific Session And Expo

FRANKLIN LAKES, N.J., March 14, 2012 /PRNewswire/ -- The final results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) study will be presented at the American College of Cardiology's 61st Annual Scientific Session & Expo being held March 24-27, 2012, in Chicago, IL. The AKROBATS study is a collaborative effort between the Medco Research Instituteā„¢, a subsidiary of Medco Health Solutions, Inc. (NYSE: MHS) and Quest Diagnostics (NYSE: DGX), the world's leading diagnostic testing company.

(Logo: )

Presentation Details

Session Number: 1258

Session Type: ACC Moderated Poster Contributions

Session Start/End Time: Monday, Mar 26, 2012, 9:30 AM -10:30 AM

Location: McCormick Place South, Hall A

Presentation Number: 1258-376 

Abstract Title: Patient knowledge of pharmacogenetic information improves adherence to statin therapy: Results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial. 

Presenter:  Scott L. Charland, Pharm.D., Medco Research Institute


AKROBATS is prospective, nonrandomized intervention trial of the effect of KIF6 testing results reported directly to the patient on statin adherence and persistence over six months.  All eligible intervention and control patients were greater than or equal to 18 years old, new to statin therapy (none 6 months prior), and from the same sponsored plans (which had granted permission for their members to participate in the study). Genetic testing for a common single nucleotide polymorphism (rs20455) resulting in an arginine to tryptophan substitution at position 719 (Trp719Arg) in the kinesin-like protein 6 gene ( KIF6) was conducted and written results returned to the patient within 30 days of initiating statin therapy, and before the first statin prescription refill.  Tested patients were matched to concurrent, non-tested control patients on age, gender, statin prescription distribution channel, and the number of chronic medications at time of statin initiation. The primary endpoint was statin adherence (proportion of days covered; PDC) at six months.  Secondary end points included achievement of adherence (PDC greater than or equal to 0.80) and persistence to statin therapy at six months.  AKROBATS is registered on (NCT01068834).

About Medco Research Institute

Medco Research Institute® is an evidence-based research organization focused solely on novel research, analytics and new discoveries that close the gap between scientific discovery and medical practice for improved patient outcomes and lower overall healthcare costs. More information about the Medco Research Institute's peer-reviewed research can be found at

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 0.00%
FB $117.81 0.00%
GOOG $701.43 0.00%
TSLA $211.53 0.00%
YHOO $36.94 0.00%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs